加载中
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
常规交易时段
US$20.9979
+US$0.1579 · +0.76%
盘中时间采用ET。市场数据可能有所延迟。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日内区间
当前US$20.9979
52周区间
当前US$20.9979
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
47
合理估值
情绪
49
多空交织
风险
52
风险偏高
动量
69
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
日内区间
当前US$20.9979
52周区间
当前US$20.9979
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 27.23亿 USD | 26.96亿 USD | 28.43亿 USD | 28.37亿 USD | 30.58亿 USD |
| 销货成本 | 22.98亿 USD | 21.62亿 USD | 22.52亿 USD | 21.13亿 USD | 24.53亿 USD |
| 毛利 | 4.26亿 USD | 5.34亿 USD | 5.91亿 USD | 7.24亿 USD | 6.04亿 USD |
| 销售、一般及管理费用 | 4.56亿 USD | 5.61亿 USD | 4.48亿 USD | 4.16亿 USD | 3.03亿 USD |
| 营业费用 | 4.56亿 USD | 6.96亿 USD | 5.59亿 USD | 5.37亿 USD | 4.9亿 USD |
| 利息支出 | 9140万 USD | 1.24亿 USD | 6980万 USD | 20万 USD | 20万 USD |
| 折旧和摊销 | 7800万 USD | 8690万 USD | 9800万 USD | 9360万 USD | 1.66亿 USD |
| 营业利润 | −3060万 USD | −1.62亿 USD | 3200万 USD | 1.87亿 USD | 1.14亿 USD |
| 净利润 | −9.86亿 USD | −3.29亿 USD | −2520万 USD | 1.86亿 USD | 9800万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.50
下跌空间 2.37%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5503.14万0.00%2.3万亿 USD0.03%US$381.54-0.10%
iShares Russell 2000 ETFIWM5248.8万0.07%787.4亿 USD0.19%US$277.91-0.37%
Vanguard Extended Market ETFVXF2014.51万0.02%954亿 USD0.05%US$233.59-0.60%
Vanguard Morningstar Small-Cap ETFVB1997.3万0.01%1853亿 USD0.03%US$288.3-0.41%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1820.03万0.11%158.4亿 USD0.03%US$53.4799+0.06%
Invesco S&P SmallCap Momentum ETFXSMO1744.46万0.61%28.69亿 USD0.35%US$81.38-0.45%
Schwab Fundamental U.S. Small Company Index ETFFNDA1616.2万0.18%87.82亿 USD0.25%US$35.605-0.04%
iShares Biotechnology ETFIBB1523.41万0.14%108.2亿 USD0.44%US$204.24-1.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMInvesco S&P SmallCap Momentum ETFXSMOSchwab Fundamental U.S. Small Company Index ETFFNDAiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
